更正：对“在工程化 NK 细胞中比较七种 CD19 CAR 设计以增强抗肿瘤活性”的更正

RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍

RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.

CD81 通过阻断 CD274/PD-L1 的选择性自噬降解驱动放射抵抗性胶质母细胞瘤的免疫逃逸

CD81 drives immune evasion in radioresistant glioblastoma by blocking selective autophagic degradation of CD274/PD-L1.

抗 CD22/CD19 CAR-T 细胞疗法 CAR-T2219.1 在成人和儿童复发/难治性 B-ALL 中的 I/II 期试验

A Phase I/II Trial of Anti-CD22/CD19 CAR-T Cell Therapy, CART2219.1, in Adult and Pediatric Relapsed/Refractory B-ALL.

靶向白血病干细胞的脂质体纳米免疫疗法通过沉默 B 细胞淋巴瘤 2 逆转免疫逃逸并抑制融合癌蛋白驱动的急性髓系白血病

Leukemic Stem Cell-Targeted Liposomal Nanoimmunotherapy Reverses Immune Evasion and Inhibits Fusion Oncoprotein-Driven Acute Myeloid Leukemia by Silen

靶向巨噬细胞的癌症治疗策略

Macrophage-directed therapeutic strategies in cancer.

决定异体 CAR T 细胞排斥与扩增的细胞和分子机制

Cellular and molecular mechanisms determining allogeneic CAR T cell rejection and expansion.

我们评估了11例接受单一批次cemacabtagene ansegedleucel（cema-cel）治疗的大B细胞淋巴瘤患者，cema-cel是一种同种异体抗CD19 CAR-T 产品。